The Master of Science (MS) program in Artificial Intelligence and Computational Drug Discovery and Development (AICD3) aims to train the next generation of scientists in advanced computational tools and methods.

Launching soon for entry in fall 2024!

This includes artificial intelligence, machine learning, bioinformatics, data science, and statistical analysis. Our mission is to empower future leaders to accelerate the discovery and development of novel therapies for diseases urgently in need of a cure.

  • Duration: 1.5 years.

  • Structure: 5 quarters:

    • 3 quarters didactic coursework.

    • 2 quarters dedicated to a capstone project.

  • Career Opportunities for Graduates:
    Graduates will emerge as leaders, driving innovation and shaping the future of academia, industry, and start-ups spearheading advancements across a spectrum of areas, from drug discovery to translational medicine.

    • Drug Discovery:

      • Use AI for target identification and validation.

      • Employ modeling techniques for lead compound optimization.

    • Drug Development:

      • Specialize in PK/PD modeling.

      • Master the nuances of pharmacometrics modeling.

    • Bioinformatics:

      • Integrate and analyze vast biological datasets.

      • Decode genomic sequences and use ML algorithms to predict protein structures.

    • Pharmacovigilance:

      • Leverage AI for real-time monitoring of drug effects.

      • Predict adverse reactions using big data analytics.

    • Translational Medicine:

      • Seamlessly bridge laboratory discoveries with patient care.

      • Harness computational tools to expedite clinical trials and tailor treatments to individual patients.